us food and drug administration: zyprexa pi

8/14/2019 US Food and Drug Administration: zyprexa PI

http://slidepdf.com/reader/full/us-food-and-drug-administration-zyprexa-pi 1/2

8/14/2019 US Food and Drug Administration: zyprexa PI

http://slidepdf.com/reader/full/us-food-and-drug-administration-zyprexa-pi 2/2

Adverse Events Occurring at an Incidence of 2% or More Among Olanzapine-Treated Patients in Short-Term, Placebo-Controlled TrialsTable 1 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse events that occurred in 2% or more of patients

treated with olanzapine (doses ≥2.5 mg/day) and with incidence greater than placebo who participated in the acute phase of placebo-controlled trials.

1 Events reported by at least 2% of patients treated with olanzapine, except the following events which had an incidence equal to or less than placebo: abdominalpain, agitation, anorexia, anxiety, apathy, confusion, depression, diarrhea, dysmenorrhea2, hallucinations, headache, hostility, hyperkinesia, myalgia, nausea,nervousness, paranoid reaction, personality disorder 3, rash, thinking abnormal, weight loss.

2 Denominator used was for females only (olanzapine,N=201; placebo,N=114).3 Personality disorder is the COSTART term for designating non-aggressive objectionable behavior.

Commonly Observed Adverse Events in Short-Term Combination TrialsIn the bipolar mania combination placebo-controlled trials, the most commonly observed adverse events associated with the combination of

olanzapine and lithium or valproate (incidence of ≥5% and at least twiceplacebo) were:

Adverse Events Occurring at an Incidence of 2% or More Among Olanzapine-Treated Patients in Short-Term Combination TrialsTable 2 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse events that occurred in 2% or more of patients

treated with the combination of olanzapine (doses ≥5 mg/day) and lithium or valproate and with incidence greater than lithium or valproate alonewho participated in the acute phase of placebo-controlled combination trials.

1 Events reported by at least 2% of patients treated with olanzapine, except the following events which had an incidence equal to or less than placebo: abdominalpain, abnormal dreams, abnormal ejaculation, agitation, akathisia, anorexia, anxiety, arthralgia, cough increased, diarrhea, dyspepsia, emotional lability, fever,flatulence, flu syndrome, headache, hostility, insomnia, libido decreased, libido increased, menstrual disorder2, myalgia, nausea, nervousness, pain, paranoidreaction, personality disorder, rash, rhinitis, sleep disorder, thinking abnormal, vomiting.

2 Denominator used was for females only (olanzapine,N=128; placebo,N=51).

For specific information about the adverse reactions observed with lithium or valproate, refer to the ADVERSE REACTIONS section of thepackage inserts for these other products.

Additional Findings Observed in Clinical TrialsThe following findings are based on clinical trials.

Dose Dependency of Adverse Events in Short-Term, Placebo-Controlled TrialsExtrapyramidal Symptoms — The following table enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as

assessed by categorical analyses of formal rating scales during acute therapy in a controlled clinical trial comparing olanzapine at 3 fixed doses withplacebo in the treatment of schizophrenia.

* No statistically significant differences.1 Percentage of patients with a Simpson-Angus Scale total score >3.2 Percentage of patients with a Barnes Akathisia Scale global score ≥2.

The following table enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as assessed by spontaneously

reported adverse events during acute therapy in the same controlled clinical trial comparing olanzapine at 3 fixed doses with placebo in thetreatment of schizophrenia.

* Statistically significantly different from placebo.1 Patients with the following COSTART terms were counted in this category: dystonia, generalized spasm, neck rigidity, oculogyric crisis, opisthotonos, torticollis.2 Patients with the following COSTART terms were counted in this category: akinesia, cogwheel rigidity, extrapyramidal syndrome, hypertonia, hypokinesia, masked

facies, tremor.3 Patients with the following COSTART terms were counted in this category: akathisia, hyperkinesia.4 Patients with the following COSTART terms were counted in this category: buccoglossal syndrome, choreoathetosis, dyskinesia, tardive dyskinesia.5 Patients with the following COSTART terms were counted in this category: movement disorder, myoclonus, twitching.

Other Adverse Events — The following table addresses dose relatedness for other adverse events using data from a schizophrenia trial involvingfixed dosage ranges. It enumerates the percentage of patients with treatment-emergent adverse events for the three fixed-dose range groups andplacebo. The data were analyzed using the Cochran-Armitage test, excluding the placebo group, and the table includes only those adverse eventsfor which there was a statistically significant trend.

Vital Sign Changes — Olanzapine is associated with orthostatic hypotension and tachycardia ( see PRECAUTIONS).

Weight Gain — In placebo-controlled, 6-week studies, weight gain was reported in 5.6% of olanzapine patients compared to 0.8% of placebo

patients. Olanzapine patients gained an average of 2.8 kg, compared to an average 0.4 kg weight loss in placebo patients; 29% of olanzapinepatients gained greater than 7% of their baseline weight, compared to 3% of placebo patients. A categorization of patients at baseline on the basis ofbody mass index (BMI) revealed a significantly greater effect in patients with low BMI compared to normal or overweight patients; nevertheless,weight gain was greater in all 3 olanzapine groups compared to the placebo group. During long-term continuation therapy with olanzapine(238 median days of exposure), 56%of olanzapine patients met the criterion for having gained greater than 7% of their baseline weight. Averageweight gain during long-term therapy was 5.4 kg.

Laboratory Changes — An assessment of the premarketing experience for olanzapine revealed an association with asymptomatic increases inSGPT, SGOT, and GGT ( see PRECAUTIONS). Olanzapine administration was also associated with increases in serum prolactin ( seePRECAUTIONS), with an asymptomatic elevation of the eosinophil count in 0.3%of patients, and with an increase in CPK.

Given the concern about neutropenia associated with other psychotropic compounds and the finding of leukopenia associated with theadministration of olanzapine in several animal models ( see ANIMAL TOXICOLOGY), careful attention was given to examination of hematologicparameters in premarketing studies with olanzapine. There was no indication of a risk of clinically significant neutropenia associated with olanzapinetreatment in the premarketing database for this drug.

ECG Changes — Between-group comparisons for pooled placebo-controlled trials revealed no statistically significant olanzapine/placebodifferences in the proportions of patients experiencing potentially important changes in ECG parameters, including QT, QTc, and PR intervals.Olanzapine use was associated with a mean increase in heart rate of 2.4 beats per minute compared to no change among placebo patients. Thisslight tendency to tachycardia may be related to olanzapine’s potential for inducing orthostatic changes ( see PRECAUTIONS).

Other Adverse Events Observed During the Clinical Trial Evaluation of OlanzapineFollowing is a list of terms that reflect treatment-emergent adverse events reported by patients treated with olanzapine (at multiple doses

≥1 mg/day) in clinical trials (8661 patients, 4165 patient-years of exposure). This listing does not include those events already listed in previoustables or elsewhere in labeling, those events for which a drug cause was remote, those event terms which were so general as to be uninformative,and those events reported only once or twice which did not have a substantial probability of being acutely life-threatening.

Events are further categorized by body system and listed in order of decreasing frequency according to the following definiti ons: frequent adverseevents are those occurring in at least 1/100 patients (only those not already listed in the tabulated results from placebo-controlled trials appear in thislisting); infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000patients.

Body as a Whole — Frequent: dental pain and flu syndrome; Infrequent: abdomen enlarged, chills, face edema, intentional injury, malaise,moniliasis, neck pain, neck rigidity, pelvic pain, photosensitivity reaction, and suicide attempt; Rare: chills and fever, hangover effect, andsudden death.

Cardiovascular System — Frequent: hypotension; Infrequent: atrial fibrillation, bradycardia, cerebrovascular accident, congestive heartfailure, heart arrest, hemorrhage, migraine, pallor, palpitation, vasodilatation, and ventricular extrasystoles; Rare: arteritis, heart failure, andpulmonary embolus.

Digestive System — Frequent: flatulence, increased salivation, and thirst; Infrequent: dysphagia, esophagitis, fecal impaction, fecalincontinence, gastritis, gastroenteritis, gingivitis, hepatitis, melena, mouth ulceration, nausea and vomiting, oral moniliasis, periodontal abscess,rectal hemorrhage, stomatitis, tongue edema, and tooth caries; Rare: aphthous stomatitis, enteritis, eructation, esophageal ulcer, glossitis, ileus,

intestinal obstruction, liver fatty deposit, and tongue discoloration.Endocrine System — Infrequent: diabetes mellitus; Rare: diabetic acidosis and goiter.

Hemic and Lymphatic System — Infrequent: anemia, cyanosis, leukocytosis, leukopenia, lymphadenopathy, and thrombocytopenia;Rare: normocytic anemia and thrombocythemia.

Metabolic and Nutritional Disorders — Infrequent: acidosis, alkaline phosphatase increased, bilirubinemia, dehydration, hypercholesteremia,hyperglycemia, hyperlipemia, hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, lower extremity edema, and upper extremity edema;Rare: gout, hyperkalemia, hypernatremia, hypoproteinemia, ketosis, and water intoxication.

Musculoskeletal System — Frequent: joint stiffness and twitching; Infrequent: arthritis, arthrosis, leg cramps, and myasthenia; Rare: bone pain,bursitis, myopathy, osteoporosis, and rheumatoid arthritis.

Nervous System — Frequent: abnormal dreams, amnesia, delusions, emotional lability, euphoria, manic reaction, paresthesia, andschizophrenic reaction; Infrequent: akinesia, alcohol misuse, antisocial reaction, ataxia, CNS stimulation, cogwheel rigidity, delirium, dementia,depersonalization, dysarthria, facial paralysis, hypesthesia, hypokinesia, hypotonia, incoordination, libido decreased, libido increased, obsessivecompulsive symptoms, phobias, somatization, stimulant misuse, stupor, stuttering, tardive dyskinesia, vertigo, and withdrawal syndrome;Rare: circumoral paresthesia, coma, encephalopathy, neuralgia, neuropathy, nystagmus, paralysis, subarachnoid hemorrhage, and tobacco misuse.

Respiratory System — Frequent: dyspnea; Infrequent: apnea, asthma, epistaxis, hemoptysis, hyperventilation, hypoxia, laryngitis, and voicealteration; Rare: atelectasis, hiccup, hypoventilation, lung edema, and stridor.

Skin and Appendages — Frequent: sweating; Infrequent: alopecia, contact dermatitis, dry skin, eczema, maculopapular rash, pruritus,seborrhea, skin discoloration, skin ulcer, urticaria, and vesiculobullous rash; Rare: hirsutism and pustular rash.

Special Senses — Frequent: conjunctivitis; Infrequent: abnormality of accommodation, blepharitis, cataract, deafness, diplopia, dry eyes, earpain, eye hemorrhage, eye inflammation, eye pain, ocular muscle abnormality, taste perversion, and tinnitus; Rare: corneal lesion, glaucoma,keratoconjunctivitis, macular hypopigmentation, miosis, mydriasis, and pigment deposits lens.

Urogenital System — Frequent: vaginitis*; Infrequent: abnormal ejaculation*, amenorrhea*, breast pain, cystitis, decreased menstruation*,dysuria, female lactation*, glycosuria, gynecomastia, hematuria, impotence*, increased menstruation*, menorrhagia*, metrorrhagia*, polyuria,premenstrual syndrome*, pyuria, urinary frequency, urinary retention, urinary urgency, urination impaired, uterine fibroids enlarged*, and vaginalhemorrhage*; Rare: albuminuria, breast enlargement, mastitis, and oliguria.

*Adjusted for gender.

Postintroduction ReportsAdverse events reported since market introduction which were temporally (but not necessarily causally) related to ZYPREXA therapy include the

following: allergic reaction (e.g., anaphylactoid reaction, angioedema, pruritus or urticaria), diabetic coma, pancreatitis, and priapism.

DRUG ABUSE AND DEPENDENCE

Controlled Substance ClassOlanzapine is not a controlled substance.

Physical and Psychological Dependence

In studies prospectively designed to assess abuse and dependence potential, olanzapine was shown to have acute depressive CNS effects butlittle or no potential of abuse or physical dependence in rats administered oral doses up to 15 times the maximum recommended human daily dose(20 mg) and rhesus monkeys administered oral doses up to 8times the maximum recommended human daily dose on a mg/m2 basis.

Olanzapine has not been systematically studied in humans for its potential for abuse, tolerance, or physical dependence. While the clinical trialsdid not reveal any tendency for any drug-seeking behavior, these observations were not systematic, and it is not possible to predict on the basis ofthis limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, patientsshould be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of misuse or abuse of olanzapine(e.g., development of tolerance, increases in dose, drug-seeking behavior).

OVERDOSAGE

Human ExperienceIn premarketing trials involving more than 3100 patients and/or normal subjects, accidental or intentional acute overdosage of olanzapine was

identified in 67 patients. In the patient taking the largest identified amount, 300 mg, the only symptoms reported were drowsiness and slurredspeech. In the limited number of patients who were evaluated in hospitals, including the patient taking 300 mg, there were no observations indicatingan adverse change in laboratory analytes or ECG. Vital signs were usually within normal limits fol lowing overdoses.

In postmarketing reports of overdose with olanzapine alone, symptoms have been reported in the majority of cases. In symptomatic patients,symptoms with ≥10% incidence included agitation/aggressiveness, dysarthria, tachycardia, various extrapyramidal symptoms, and reduced level ofconsciousness ranging from sedation to coma. Among less commonly reported symptoms were the following potentially medically serious events:aspiration, cardiopulmonary arrest, cardiac arrhythmias (such as supraventricular tachycardia and one patient experiencing sinus pause withspontaneous resumption of normal rhythm), delirium, possible neuroleptic malignant syndrome, respiratory depression/arrest, convulsion,hypertension, and hypotension. Eli Lilly and Company has received reports of fatality in association with overdose of olanzapine alone. In one caseof death, the amount of acutely ingested olanzapine was reported to be possibly as low as 450 mg; however, in another case, a patient was reportedto survive an acute olanzapine ingestion of 1500 mg.

Overdosage ManagementThe possibility of multiple drug involvement should be considered. In case of acute overdosage, establish and maintain an airway and ensure

adequate oxygenation and ventilation, which may include intubation. Gastric lavage (after intubation, if patient is unconscious) and administration ofactivated charcoal together with a laxative should be considered. The possibility of obtundation, seizures, or dystonic reaction of the head and neckfollowing overdose may create a risk of aspiration with induced emesis. Cardiovascular monitoring should commence immediately and shouldinclude continuous electrocardiographic monitoring to detect possible arrhythmias.

There is no specific antidote to olanzapine. Therefore, appropriate supportive measures should be initiated. Hypotension and circulatory collapseshould be treated with appropriate measures such as intravenous fluids and/or sympathomimetic agents. (Do not use epinephrine, dopamine, orother sympathomimetics with beta-agonist activity, since beta stimulation may worsen hypotension in the setting of olanzapine-induced alphablockade.) Close medical supervision and monitoring should continue until the patient recovers.

DOSAGE AND ADMINISTRATION

Schizophrenia

Usual Dose — Olanzapine should be administered on a once-a-day schedule without regard to meals, generally beginning with 5 to 10 mginitially, with a target dose of 10 mg/day within several days. Further dosage adjustments, if indicated, should generally occur at intervals of not l essthan 1 week, since steady state for olanzapine would not be achieved for approximately 1 week in the typical patient. When dosage adjustments arenecessary, dose increments/decrements of 5 mg QD are recommended.

Efficacy in schizophrenia was demonstrated in a dose range of 10 to 15 mg/day in clinical trials. However, doses above 10 mg/day were notdemonstrated to be more efficacious than the 10 mg/day dose. An increase to a dose greater than the target dose of 10 mg/day (i.e., to a dose of15 mg/day or greater) is recommended only after clinical assessment. The safety of doses above 20mg/day has not been evaluated in clinical trials.

Dosing in Special Populations — The recommended starting dose is 5 mg in patients who are debilitated, who have a predisposition tohypotensive reactions, who otherwise exhibit a combination of factors that may result in slower metabolism of olanzapine (e.g., nonsmoking femalepatients ≥65 years of age), or who may be more pharmacodynamically sensitive to olanzapine ( see CLINICAL PHARMACOLOGY; also see Use inPatients with Concomitant Illness and Drug Interactions under PRECAUTIONS). When indicated, dose escalation should be performed with cautionin these patients.

Maintenance Treatment — While there is no body of evidence available to answer the question of how long the patient treated with olanzapineshould remain on it, the effectiveness of oral olanzapine, 10 mg/day to 20 mg/day, in maintaining treatment response in schizophrenic patients whohad been stable on ZYPREXA for approximately 8 weeks and were then followed for a period of up to 8 months has been demonstrated in aplacebo-controlled trial ( see CLINICAL PHARMACOLOGY). Patients should be periodically reassessed to determine the need for maintenancetreatment with appropriate dose.

Bipolar DisorderUsual Monotherapy Dose — Olanzapine should be administered on a once-a-day schedule without regard to meals, generally beginning with

10 or 15 mg. Dosage adjustments, if indicated, should generally occur at intervals of not less than 24 hours, reflecting the procedures in theplacebo-controlled trials. When dosage adjustments are necessary, dose increments/decrements of 5 mg QD are recommended.

Short-term (3-4 weeks) antimanic efficacy was demonstrated in a dose range of 5 mg to 20 mg/day in clinical trials. The safety of doses above20 mg/day has not been evaluated in clinical trials.

Maintenance Monotherapy — The benefit of maintaining bipolar patients on monotherapy with ZYPREXA at a dose of 5 to 20 mg/day, afterachieving a responder status for an average duration of two weeks, was demonstrated in a controlled trial ( see Clinical Efficacy Data under CLINICAL PHARMACOLOGY). The physician who elects to use ZYPREXA for extended periods should periodically re-evaluate the long-termusefulness of the drug for the individual patient.

Bipolar Mania Usual Dose in Combination with Lithium or Valproate — When administered in combination with lithium or valproate, olanzapinedosing should generally begin with 10 mg once-a-day without regard to meals.

Short-term (6 weeks) antimanic efficacy was demonstrated in a dose range of 5 mg to 20 mg/day in clinical trials. The safety of doses above20 mg/day has not been evaluated in clinical trials.

Dosing in Special Populations — See Dosing in Special Populations under DOSAGE AND ADMINISTRATION, Schizophrenia.

Administration of ZYPREXA ZYDIS (olanzapine orally disintegrating tablets)

After opening sachet, peel back foil on blister. Do not push tablet through foil. Immediately upon opening the blister, using dry hands,

remove tablet and place entire ZYPREXA ZYDIS in the mouth. Tablet disintegration occurs rapidly in saliva so it can be easily swallowed withor without liquid.

HOW SUPPLIEDThe ZYPREXA 2.5 mg, 5 mg, 7.5 mg, and 10 mg tablets are white, round, and imprinted in blue ink with LILLY and tablet number. The 15 mg

tablets are elliptical, blue, and debossed with LILLY and tablet number. The 20 mg tablets are elliptical, pink, and debossed with LILLY and tabletnumber. The tablets are available as follows:

*Identi-Dose ® (unit dose medication, Lilly).

ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) are yellow, round, and debossed with the tablet strength. The tablets areavailable as follows:

ZYPREXA is a registered trademark of Eli Lilly and Company.

ZYDIS is a registered trademark of R. P. SchererCorporation.

*ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) is manufactured for Eli Lilly and Company by Scherer DDS Limited, United Kingdom,SN58RU.

Store at controlled room temperature, 20° t o25°C (68° t o77°F) [ see USP]. The USP defines controlled room temperature as a temperaturemaintained thermostatically that encompasses the usual and customary working environment of 20 ° to25°C (68° to77°F); that results in a meankinetic temperature calculated to be not more than 25°C; and that allows for excursions between 15° and 30°C (59° and 86°F) that are experiencedin pharmacies, hospitals, and warehouses.

Protect from light and moisture.

ANIMAL TOXICOLOGYIn animal studies with olanzapine, the principal hematologic findings were reversible peripheral cytopenias in individual dogs dosed at 10 mg/kg

(17 times the maximum recommended human daily dose on a mg/m2 basis), dose-related decreases in lymphocytes and neutrophils in mice, andlymphopenia in rats. A few dogs treated with 10 mg/kg developed reversible neutropenia and/or reversible hemolytic anemia between 1 and10 months of treatment. Dose-related decreases in lymphocytes and neutrophils were seen in mice given doses of 10 mg/kg (equal to 2 times themaximum recommended human daily dose on a mg/m2 basis) in studies of 3 months’ duration. Nonspecific lymphopenia, consistent with decreasedbody weight gain, occurred in rats receiving 22.5 mg/kg (11 times the maximum recommended human daily dose on a mg/m2 basis) for 3months or16 mg/kg (8 times the maximum recommended human daily dose on a mg/m2 basis) for 6or 12 months. No evidence of bone marrow cytotoxicitywas found in any of the species examined. Bone marrows were normocellular or hypercellular, indicating that the reductions in circulating blood cellswere probably due to peripheral (non-marrow) factors.

Literature revised January 14, 2004

Eli Lilly and CompanyIndianapolis, IN 46285, USA

www.ZYPREXA.com

PV 3393 AMP PRINTED IN USA

Copyright © 1997, 2004, Eli Lilly and Company. All rights reserved.

ZYPREXA ® (Olanzapine) TabletsZYPREXA ® ZYDIS ® (Olanzapine) Orally Disintegrating Tablets

ZYPREXA ® (Olanzapine) TabletsZYPREXA ® ZYDIS ® (Olanzapine) Orally Disintegrating Tablets

Asthenia 15 6

Dry mouth 22 7

Constipation 11 5

Dyspepsia 11 5Increased appetite 6 3

Somnolence 35 13

Dizziness 18 6

Tremor 6 3

Body as a Whole

Accidental injury 12 8

Asthenia 10 9

Fever 6 2

Back pain 5 2

Chest pain 3 1

Cardiovascular System

Postural hypotension 3 1

Tachycardia 3 1

Hypertension 2 1

Digestive System

Dry mouth 9 5

Constipation 9 4

Dyspepsia 7 5

Vomiting 4 3

Increased appetite 3 2

Hemic and Lymphatic System

Ecchymosis 5 3

Metabolic and Nutritional Disorders

Weight gain 5 3

Peripheral edema 3 1

Musculoskeletal System

Extremity pain (other than joint) 5 3

Joint pain 5 3

Nervous System

Somnolence 29 13

Insomnia 12 11

Dizziness 11 4

Abnormal gait 6 1

Tremor 4 3

Akathisia 3 2

Hypertonia 3 2

Articulation impairment 2 1

Respiratory System

Rhinitis 7 6

Cough increased 6 3

Pharyngitis 4 3

Special Senses

Amblyopia 3 2

Urogenital System

Urinary incontinence 2 1

Urinary tract infection 2 1

Dry mouth 32 9

Weight gain 26 7


Dizziness 14 7

Back pain 8 4

Constipation 8 4

Speech disorder 7 1

Increased salivation 6 2

Amnesia 5 2

Paresthesia 5 2

Body as a Whole

Asthenia 18 13

Back pain 8 4

Accidental injury 4 2

Chest pain 3 2

Cardiovascular System

Hypertension 2 1

Digestive System

Dry mouth 32 9


Thirst 10 6

Constipation 8 4

Increased salivation 6 2

Metabolic and Nutritional Disorders

Weight gain 26 7

Peripheral edema 6 4

Edema 2 1

Nervous System

Somnolence 52 27

Tremor 23 13

Depression 18 17

Dizziness 14 7

Speech disorder 7 1

Amnesia 5 2

Paresthesia 5 2

Apathy 4 3

Confusion 4 1

Euphoria 3 2

Incoordination 2 0

Respiratory System

Pharyngitis 4 1

Dyspnea 3 1

Skin and Appendages

Sweating 3 1

Acne 2 0

Dry skin 2 0

Special Senses

Amblyopia 9 5

Abnormal vision 2 0

Urogenital System

Dysmenorrhea2 2 0

Vaginitis2 2 0

Parkinsonism1 15 14 12 14

Akathisia2 23 16 19 27

Dystonic events1 1 3 2 3

Parkinsonism events2 10 8 14 20

Akathisia events3 1 5 11* 10*

Dyskinetic events4 4 0 2 1

Residual events5 1 2 5 1

Any extrapyramidal event 16 15 25 32*

Asthenia 15 8 9 20

Dry mouth 4 3 5 13

Nausea 9 0 2 9

Somnolence 16 20 30 39

Tremor 3 0 5 7

2.5 mg 5 mg 7.5 mg 10 mg 15 mg 20 mg

Tablet No. 4112 4115 4116 4117 4415 4420

Identification LILLY LILLY LILLY LILLY LILLY LILLY

4112 4115 4116 4117 4415 4420

NDC Codes:

Bottles 60 NDC 0002- NDC 0002- NDC 0002- NDC 0002- NDC 0002- NDC 0002-

4112-60 4115-60 4116-60 4117-60 4415-60 4420-60

Blisters - NDC 0002- NDC 0002- NDC 0002- NDC 0002- NDC 0002- NDC 0002-

ID* 100 4112-33 4115-33 4116-33 4117-33 4415-33 4420-33

Bottles 1000 NDC 0002- NDC 0002- NDC 0002- NDC 0002- NDC 0002- NDC 0002-

4112-04 4115-04 4116-04 4117-04 4415-04 4420-04

ZYPREXA ZYDIS

Tablets* 5 mg 10 mg 15 mg 20 mg

Tablet No. 4453 4454 4455 4456

Debossed 5 10 15 20

NDC Codes:

Dose Pack 30 NDC 0002- NDC 0002- NDC 0002- NDC 0002-

(Child-Resistant) 4453-85 4454-85 4455-85 4456-85

Common Treatment-Emergent Adverse Events Associated with theUse of Olanzapine in 3-Week and 4-Week Trials — BIPOLAR MANIA

Percentage of Patients Reporting Event

Adverse Event Olanzapine(N=125)

Placebo(N=129)

Table 1Treatment-Emergent Adverse Events:

Incidence in Short-Term, Placebo-Controlled Clinical Trials1


Olanzapine(N=532)

Placebo(N=294)Body System/Adverse Event

Common Treatment-Emergent Adverse Events Associated with theUse of Olanzapine in 6-Week Combination Trials — BIPOLAR MANIA


Olanzapine withlithium or valproate

(N=229)

Placebo withlithium or valproate

(N=115)

Adverse Event

Table 2Treatment-Emergent Adverse Events:

Incidence in Short-Term, Placebo-Controlled Combination Clinical Trials1


Body System/Adverse Event

Olanzapine withlithium or valproate

(N=229)

Placebo withlithium or valproate

(N=115)

TREATMENT-EMERGENT EXTRAPYRAMIDAL SYMPTOMS ASSESSED BY RATINGSCALES INCIDENCE IN A FIXED DOSAGE RANGE, PLACEBO-CONTROLLED

CLINICAL TRIAL — ACUTE PHASE*


Placebo

Olanzapine5 ± 2.5 mg/day



TREATMENT-EMERGENT EXTRAPYRAMIDAL SYMPTOMS ASSESSED BY ADVERSEEVENTS INCIDENCE IN A FIXED DOSAGE RANGE, PLACEBO-CONTROLLED

CLINICAL TRIAL — ACUTE PHASE


Placebo(N=68)


(N=65)


(N=64)


(N=69)


Adverse Event Placebo(N=68)


(N=65)


(N=64)


(N=69)

TABLET STRENGTH

TABLET STRENGTH

PV3393AMP-4.qxd 2/6/04 9:28 AM

us food and drug administration: zyprexa pi

Documents